Michel Detheux
2022
In 2022, Michel Detheux earned a total compensation of $10.5M as Ph.D. Chief Executive Officer at iTeos Therapeutics, a 88% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $310,897 |
|---|---|
| Option Awards | $9,227,886 |
| Salary | $555,729 |
| Stock Awards | $358,600 |
| Other | $55,757 |
| Total | $10,508,869 |
Detheux received $9.2M in option awards, accounting for 88% of the total pay in 2022.
Detheux also received $310.9K in non-equity incentive plan, $555.7K in salary, $358.6K in stock awards and $55.8K in other compensation.
Rankings
In 2022, Michel Detheux's compensation ranked 231st out of 5,575 executives tracked by ExecPay. In other words, Detheux earned more than 95.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 231 out of 5,575 | 96th |
Division Manufacturing | 89 out of 3,027 | 97th |
Major group Chemicals And Allied Products | 18 out of 1,363 | 99th |
Industry group Drugs | 14 out of 1,266 | 99th |
Industry Biological Products, Except Diagnostic Substances | 4 out of 290 | 99th |
Source: SEC filing on April 27, 2023.
Detheux's colleagues
We found two more compensation records of executives who worked with Michel Detheux at iTeos Therapeutics in 2022.
News
iTeos Therapeutics CEO Michel Detheux's 2023 pay falls 45% to $5.8M
April 25, 2024
iTeos Therapeutics CEO Michel Detheux's 2022 pay jumps 88% to $11M
April 27, 2023
iTeos Therapeutics CEO Michel Detheux's 2021 pay falls 67% to $5.6M
April 25, 2022
iTeos Therapeutics CEO Michel Detheux's 2020 pay jumps 964% to $17M
May 5, 2021